FTC’s Ban of Noncompete Agreements Halted
With the rule recently struck down by a Texas court, how should employers, including labs, handle such agreements going forward?
Essential
Subscribe today for access to
Articles and Reports
Six Sigma Can Help Monitor New CLIA Proficiency Testing Changes
A PT update went into effect on January 1, focusing on revised acceptance limits, among other modifications
ProPhase Labs’ Resolution for 2025: Nail Down a ‘Liquidity Event’
The company has lost nearly $36 million since 2023, but its CEO is aggressively pursuing new revenue options
The Year in Labs Regulation: The 6 Biggest Stories of 2019
"May you live...
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will apparently continue as stand-alones in the coming year, one because it wants to and the other because it has to.
Alabama Doctors, Cardio Practice, Settle Genetic Testing Kickback Claims for $1.1 Million
...
Already a member? Log in here
Texas Scammer Gets 20 Years for Role in $50 Million Lab Test Ripoff
...
Already a member? Log in here
Kickbacks: Millennium Free Test Cup Physicians Crackdown Yields First 7-Figure Settlement
The federal crackdown against the physicians and medical practices that accepted free point-of-care test cups from Millennium Health continues. On Oct. 2, 2019, the OIG dropped a bombshell by announcing that
Compliance Perspectives: 5 Ways to Avoid Kickback Risks When Placing Phlebotomists in Ordering Physician’s Offices
It’s not uncommon for labs to place a phlebotomist in a physician’s office to collect and process samples for testing. While not strictly illegal, this practice raises bright red flags under kickback laws. So, it’s imperative to carefully vet your in-office phlebotomist arrangements to ensure they don’t cross any kickback lines.
Feds Take Down Florida Substance Abuse Clinic Principles for Drug Test Fraud
...
Already a member? Log in here
The DX Pipeline: A roundup of the month’s key new product launches
The last quarter is typically the busiest of the year for new product launches and 2019 is no exception. The DX pipeline was churning at a high pace from late October to mid-November. Here’s a rundown of the key product launches
FDA Watch: Agency Clears the Way for Approval of Blood-Based PSA Test
The U.S. Preventive Services Task Force (USPTF) recommends that men age 55 to 65 consider prostate cancer screening. The reason it doesn’t directly recommend testing for all men in this age group is that current screening methods that rely on detecting high levels of
DX Earnings Report: Lab Market Consolidates but Survivors Stay Strong
PAMA and private payor rate cuts and increased market competitiveness are fueling consolidation and driving smaller, independent labs (other than specialty labs) into near extinction. But the big, established companies continue to chug along, not only via acquisition revenues but
